International Journal of Medical Toxicology and Forensic Medicine

[1] Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos MD. Toxicity of amphetamines: an update. Archives of Toxicology. 2012;86(8):1167-231. [DOI: 10.1007/s00204-012-0815-5]

[2] Hashisha R, Hassan H, Ali S. Crystal methamphetamine abuse among patients attending Ismailia mental health clinic: Aggressive behavior and psychiatric comorbidity. Ain Shams Journal of Forensic Medicine and Clinical Toxicology. 2022;39(2):48-55. [Link]

[3] Jones CM, Houry D, Han B, Baldwin G, Vivolo‐Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Annals of the New York Academy of Sciences. 2022;1508(1):3-22. [DOI: 10.1111/nyas.14664]

[4] Northrop NA, Yamamoto BK. Methamphetamine effects on blood-brain barrier structure and function. Frontiers in neuroscience. 2015;9:69. [DOI: 10.3389/fnins.2015.00069]

[5] Vearrier D, Greenberg MI, Miller SN, Okaneku JT, Haggerty DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Disease-a-month. 2012;58(2):38-89. [DOI: 10.1016/j.disamonth.2011.09.004]

[6] Wang T, Shen B, Wu H, Hu J, Xu H, Shen M, Xiang P. Disappearance of R/S-methamphetamine and R/S-amphetamine from human scalp hair after discontinuation of methamphetamine abuse. Forensic Science International. 2018;284:153-60. [DOI: 10.1016/j.forsciint.2017.12.009]

[7] Chomchai C, Chomchai S, Kitsommart R. Transfer of methamphetamine (MA) into breast milk and urine of postpartum women who smoked MA tablets during pregnancy: implications for initiation of breastfeeding. Journal of Human Lactation. 2016;32(2):333-9. [DOI: 10.1177/0890334415618949]

[8] Bartu A, Dusci LJ, Ilett KF. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. British Journal of Clinical Pharmacology. 2009;67(4):455-9. [DOI: 10.1111/j.1365-2125.2009.03389.x]

[9] Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, Alexoff D. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PloS one. 2010;5(12):e15269. [DOI: 10.1371/journal.pone.0015269]

[10] Abbruscato TJ, Trippier PC. DARK classics in chemical neuroscience: methamphetamine. ACS Chemical Neuroscience. 2018;9(10):2373-8. [DOI: 10.1021/acschemneuro.8b00214]

[11] De La Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farré M. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?. Frontiers in genetics. 2012;3:235. [DOI: 10.3389/fgene.2012.00235]

[12] Shima N, Tsutsumi H, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H. Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users' urine. Journal of Chromatography B. 2006;830(1):64-70. [DOI: 10.1016/j.jchromb.2005.10.046]

[13] Wagner DJ, Sager JE, Duan H, Isoherranen N, Wang J. Interaction and transport of methamphetamine and its primary metabolites by organic cation and multidrug and toxin extrusion transporters. Drug metabolism and disposition. 2017;45(7):770-8. [DOI: 10.1124/dmd.117.075523]

[14] Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The bioavailability of intranasal and smoked methamphetamine. Clinical pharmacology & therapeutics. 2003;74(5):475-86. [DOI: 10.1016/S0009-9236(03)00225-2]

[15] Moszczynska A. Current and emerging treatments for methamphetamine use disorder. Current neuropharmacology. 2021;19(12):2077-91. [DOI: 10.2174/1570159X19666210318124321]

[16] Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegeneration. International review of neurobiology. 2009;88:101-19. [DOI: 10.1016/S0074-7742(09)88005-7]

[17] Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug and alcohol dependence. 2013;129(3):167-79. [DOI: 10.1016/j.drugalcdep.2012.11.003]

[18] Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, Tizabi Y, Costa G, Morelli M. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Progress in neurobiology. 2017;155:149-70. [DOI: 10.1016/j.pneurobio.2015.12.002]

[19] Moszczynska A, Callan SP. Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment. The Journal of pharmacology and experimental therapeutics. 2017 Sep 1;362(3):474-88. [DOI: 10.1124/jpet.116.237271]

[20] Curran L, Nah G, Marcus GM, Tseng Z, Crawford MH, Parikh NI. Clinical Correlates and Outcomes of Methamphetamine‐Associated Cardiovascular Diseases in Hospitalized Patients in California. Journal of the American Heart Association. 2022;11(16):e023663. [DOI: 10.1161/JAHA.121.023663]

[21] Batra V, Murnane KS, Knox B, et al. Early-onset Cardiovascular Disease Related to Methamphetamine use is most Striking in Individuals under 30: A retrospective chart review. Addict Behav Rep. 2022;15:100435. [DOI: 10.1016/j.abrep.2022.100435]

[22] Jariwal R, Narang V, Raza N, Mann B, Bhandohal J, Valdez M, Win TT, Joolhar FS, Ghandforoush A, Narang VK. Echocardiographic findings in heart failure patients with methamphetamine use: a case-control study. Cureus. 2021;13(7). [DOI: 10.7759/cureus.16170]

[23] Bhatia HS, Nishimura M, Dickson S, Adler E, Greenberg B, Thomas IC. Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart. 2021;107(9):741-7. [DOI: 10.1136/heartjnl-2020-317899]

[24] Yu H, Peng Y, Dong W, Shen B, Yang G, Nie Q, Tian Y, Qin L, Song C, Chen B, Zhao Y. Nrf2 attenuates methamphetamine-induced myocardial injury by regulating oxidative stress and apoptosis in mice. Human & Experimental Toxicology. 2023;42:09603271231219488. [DOI: 10.1177/09603271231219488]

[25] Kolluru GK, Glawe JD, Pardue S, Kasabali A, Alam S, Rajendran S, Cannon AL, Abdullah CS, Traylor JG, Shackelford RE, Woolard MD. Methamphetamine causes cardiovascular dysfunction via cystathionine gamma lyase and hydrogen sulfide depletion. Redox biology. 2022;57:102480. [DOI: 10.1016/j.redox.2022.102480]

[26] Abdullah CS, Aishwarya R, Alam S, Morshed M, Remex NS, Nitu S, Kolluru GK, Traylor J, Miriyala S, Panchatcharam M, Hartman B. Methamphetamine induces cardiomyopathy by Sigmar1 inhibition-dependent impairment of mitochondrial dynamics and function. Communications biology. 2020;3(1):682. [DOI: 10.1038/s42003-020-01408-x]

[27] Akhgari M, Mobaraki H, Etemadi-Aleagha A. Histopathological study of cardiac lesions in methamphetamine poisoning-related deaths. DARU Journal of Pharmaceutical Sciences. 2017;25(1):5. [DOI: 10.1186/s40199-017-0168-0]

[28] Zhao T, Zhai C, Song H, Wu Y, Ge C, Zhang Y, Xu H, Chi Z, Chu H, Shi W, Cheng X. Methamphetamine-induced cognitive deficits and psychiatric symptoms are associated with serum markers of liver damage. Neurotoxicity Research. 2020;37(1):67-76. [DOI: 10.1007/s12640-019-00063-9]

[29] Chen LJ, Li XW, Liu Y, Liu JL, Yang JZ, Li JH, Hsu C, Chen L, Zeng JH, Xie XL, Wang Q. Propionate, rather than acetate or butyrate, ameliorates methamphetamine-induced hepatotoxicity and enterotoxicity in mice by downregulating the TLR4/NF-κB pathway. Journal of Functional Foods. 2023;109:105796. [DOI: 10.1016/j.jff.2023.105796]

[30] Carvalho M, Milhazes N, Remião F, Borges F, Fernandes E, Amado F, Monks TJ, Carvalho F, Bastos ML. Hepatotoxicity of 3, 4-methylenedioxyamphetamine and α-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Archives of Toxicology. 2004;78(1):16-24. [DOI: 10.1007/s00204-003-0495-y]

[31] Paknahad S, Akhgari M, Ghadipasha M. An alarming rise in the prevalence of deaths with methamphetamine involved in Tehran, Iran, 2011-2018. Forensic Science, Medicine, and Pathology. 2021;17(2):208-15. [DOI: 10.1007/s12024-020-00355-0]

[32] Kunalan V, Nic Daeid N, Kerr WJ, Buchanan HA, McPherson AR. Characterization of route-specific impurities found in methamphetamine synthesized by the Leuckart and reductive amination methods. Analytical chemistry. 2009;81(17):7342-8. [DOI: 10.1021/ac901009n]

[33] Ko BJ, Suh S, Suh YJ, In MK, Kim SH. The impurity characteristics of methamphetamine synthesized by Emde and Nagai method. Forensic Science International. 2007;170(2-3):142-7. [DOI: 10.1016/j.forsciint.2007.04.019]

[34] Lee JS, Han EY, Lee SY, Kim EM, Park YH, Lim MA, Chung HS, Park JH. Analysis of the impurities in the methamphetamine synthesized by three different methods from ephedrine and pseudoephedrine. Forensic Science International. 2006;161(2-3):209-15. [DOI: 10.1016/j.forsciint.2006.01.017]

[35] Hazama S, Ichikawa S, Yonebayashi F. Convenient method for synthesis of L-Methamphetamine. Japanese Journal of Forensic Science and Technology. 2008;13(1):67-72. [DOI: 10.3408/jafst.13.67]

[36] Cantrell TS, John B, Johnson L, Allen AC. A study of impurities found in methamphetamine synthesized from ephedrine. Forensic Science International. 1988;39(1):39-53. [DOI: 10.1016/0379-0738(88)90164-2]

[37] Toske SG, McKibben TD. Monitoring methamphetamine in the United States: a two‐decade review as seen by the DEA methamphetamine profiling program. Drug testing and analysis. 2022;14(3):416-26. [DOI: 10.1002/dta.3167]

[38] Moore KA, Lichtman AH, Poklis A, Borzelleca JF. α-Benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: pharmacological evaluation and interaction with methamphetamine. Drug and alcohol dependence. 1995;39(2):83-9. [DOI: 10.1016/0376-8716(95)01123-3]

[39] Langone D, Painter B, Nash C, Hulshof J, Oldenhof S, Johnston MR, Kirkbride KP. Impurity profiling of methamphetamine synthesized from methyl α‐acetylphenylacetate. Drug Testing and Analysis. 2022;14(7):1310-24. [DOI: 10.1002/dta.3272]

[40] Moore KA, Soine WH, Poklis A. (α-Benzyl-N-Methylphenethylamine (BNMPA), an Impurity of Illicit Methamphetamine Synthesis: I. Physical Characterization and GC-MS Analysis of BNMPA and Anticipated Metabolites in Urine. Journal of Analytical Toxicology. 1995;19(7):542-8. [DOI: 10.1093/jat/19.7.542]

[41] Barron RP, Kruegel AV, Moore JM, Kram TC. Identification of impurities in illicit methamphetamine samples. Journal of the Association of Official Analytical Chemists. 1974;57(5):1147-58.

[42] Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological reviews. 2003;55(3):463-508. [DOI: 10.1124/pr.55.3.3]

[43] Nichols DE. Entactogens: How the name for a novel class of psychoactive agents originated. Frontiers in psychiatry. 2022;13:863088. [DOI: 10.3389/fpsyt.2022.863088]

[44] Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity. Toxicology Letters. 2011;205:S26. [DOI: 10.1016/j.toxlet.2011.05.596]

[45] Montgomery C, Roberts CA. Neurological and cognitive alterations induced by MDMA in humans. Experimental Neurology. 2022;347:113888. [DOI: 10.1016/j.expneurol.2021.113888]

[46] Bickel J, Müller A, Jungen H, Szewczyk A, Teske J, Küpper U, Andresen-Streichert H, Ondruschka B, Iwersen-Bergmann S. Post mortem chiral analysis of MDMA and MDA in human blood and hair. Forensic science international. 2024;364:112226. [DOI: 10.1016/j.forsciint.2023.112226]

[47] Den Hollander B. Neuropharmacology and toxicology of novel amphetamine-type stimulants. [Link]

[48] Jamali B, Torkamanian M, Badri N, Sheikholeslami B, Ardakani YH, Rouini MR. Assays for MDMA and Its Metabolites. In Neuropathology of Drug Addictions and Substance Misuse 2016 Jan 1 (pp. 503-512). Academic Press. [DOI: 10.1016/B978-0-12-800213-1.00047-7]

[49] Nielsen KL, Telving R, Andreasen MF, Hasselstrøm JB, Johannsen M. A metabolomics study of retrospective forensic data from whole blood samples of humans exposed to 3, 4-methylenedioxymethamphetamine: a new approach for identifying drug metabolites and changes in metabolism related to drug consumption. Journal of Proteome Research. 2016;15(2):619-27. [DOI: 10.1021/acs.jproteome.5b00843]

[50] De la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Therapeutic drug monitoring. 2004;26(2):137-44. [DOI: 10.1097/00007691-200404000-00007]

[51] Steuer AE, Schmidhauser C, Schmid Y, Rickli A, Liechti ME, Kraemer T. Chiral plasma pharmacokinetics of 3, 4-methylenedioxymethamphetamine and its phase I and II metabolites following controlled administration to humans. Drug metabolism and disposition. 2015;43(12):1864-71. [DOI: 10.1124/dmd.115.065763]

[52] Steuer AE, Schmidhauser C, Tingelhoff EH, Schmid Y, Rickli A, Kraemer T, Liechti ME. Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3, 4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans. PloS one. 2016;11(3):e0150955. [DOI: 10.1371/journal.pone.0150955]

[53] Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. American Journal of Human Genetics. 1997;60(2):284. [Link]

[54] Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clinical pharmacokinetics. 2009;48(12):761-804. [DOI: 10.2165/11318030-000000000-00000]

[55] Drevin G, Hahn O, Picard N, Baudriller A, Renard L, Malbranque S, Jousset N, Briet M, Abbara C. Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report. Forensic Science International: Genetics. 2025;76:103219. [DOI: 10.1016/j.fsigen.2024.103219]

[56] Roxburgh A, Sam B, Kriikku P, Mounteney J, Castanera A, Dias M, Giraudon I. Trends in MDMA‐related mortality across four countries. Addiction. 2021;116(11):3094-103. [DOI: 10.1111/add.15457]

[57] Roxburgh A, Lappin J. MDMA-related deaths in Australia 2000 to 2018. International Journal of Drug Policy. 2020;76:102630. [DOI: 10.1016/j.drugpo.2019.102630]

[58] Di Nunno N, Esposito M, Argo A, Salerno M, Sessa F. Pharmacogenetics and forensic toxicology: A new step towards a multidisciplinary approach. Toxics. 2021;9(11):292. [DOI: 10.3390/toxics9110292]

[59] Bertol E, Mari F, Di Milia MG, Politi L, Furlanetto S, Karch SB. Determination of aminorex in human urine samples by GC–MS after use of levamisole. Journal of pharmaceutical and biomedical analysis. 2011;55(5):1186-9. [DOI: 10.1016/j.jpba.2011.03.044]

[60] Hess C, Ritke N, Broecker S, Madea B, Musshoff F. Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS. Analytical and Bioanalytical Chemistry. 2013;405(12):4077-88. [DOI: 10.1007/s00216-013-6845-z]

[61] Rothman RB, Baumann MH. Serotonin-releasing agents: neurochemical, therapeutic, and adverse effects. Pharmacology, Biochemistry, and Behavior. 2002;71(4):825-36. [DOI: 10.1016/S0091-3057(01)00758-1]

[62] Buchanan JA, Oyer RJ, Patel NR, Jacquet GA, Bornikova L, Thienelt C, Shriver DA, Shockley LW, Wilson ML, Hurlbut KM, Lavonas EJ. A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole. Journal of Medical Toxicology. 2010;6(2):160-4. [DOI: 10.1007/s13181-010-0062-z]

[63] Chai PR, Bastan W, Machan J, Hack JB, Babu KM. Levamisole exposure and hematologic indices in cocaine users. Academic Emergency Medicine. 2011;18(11):1141-7. [DOI: 10.1111/j.1553-2712.2011.01223.x]

[64] Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation. 1999;100(8):869-75. [DOI: 10.1161/01.CIR.100.8.869]

[65] Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS. Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32-41. [DOI: 10.1002/1098-2396(200101)39:1<32::AID-SYN5>3.0.CO;2-4]

[66] Glanville J, Dargan PI, Wood DM. 4‐Methyl‐5‐(4‐methylphenyl)‐4, 5‐dihydrooxazol‐2‐amine (4, 4′‐DMAR, 4, 4′‐dimethylaminorex): availability, prevalence of use, desired effects, and acute toxicity. Human Psychopharmacology: Clinical and Experimental. 2015;30(3):193-8. [DOI: 10.1002/hup.2455]

[67] Loi B, Zloh M, De Luca MA, Pintori N, Corkery J, Schifano F. 4, 4′‐Dimethylaminorex ("4, 4′‐DMAR"; "Serotoni") misuse: A Web‐based study. Human Psychopharmacology: Clinical and Experimental. 2017;32(3):e2575. [DOI: 10.1002/hup.2575]

[68] Maier J, Mayer FP, Brandt SD, Sitte HH. DARK classics in chemical neuroscience: aminorex analogues. ACS Chemical Neuroscience. 2018;9(10):2484-502. [DOI: 10.1021/acschemneuro.8b00254]

[69] Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA. Recreational use of aminorex and pulmonary hypertension. Chest. 2000;118(5):1496-7. [DOI: 10.1378/chest.118.5.1496]

[70] Cosbey S, Kirk S, McNaul M, Peters L, Prentice B, Quinn A, Elliott SP, Brandt SD, Archer RP. Multiple fatalities involving a new designer drug: para-methyl-4-methylaminorex. Journal of Analytical Toxicology. 2014;38(6):383-4. [DOI: 10.1093/jat/bku043]

[71] Davis FT, Brewster ME. A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. Journal of Forensic Sciences. 1988;33(2):549-53. [DOI: 10.1520/JFS12056J]